Evidence map›Paper›PMID 39203468›Full record

ArticleMicroorganisms2024

The Anti-Constipation Effect of Bifidobacterium Longum W11 Is Likely Due to a Key Genetic Factor Governing Arabinan Utilization.

Francesco Di Pierro, Nicola Zerbinati, Massimiliano Cazzaniga, Alexander Bertuccioli, Chiara Maria Palazzi, Ilaria Cavecchia, Mariarosaria Matera, Edoardo Labrini, Valeria Sagheddu, Sara Soldi

Abstract read
In one paragraph

Article in Microorganisms, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Frontiers in microbiology · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Francesco Di PierroMicrobiota International Clinical Society, 10123 Torino, Italy.ORCID 0000-0001-6654-8675
Nicola ZerbinatiDepartment of Medicine and Technological Innovation, University of Insubria, 21100 Varese, Italy.
Massimiliano CazzanigaScientific & Research Department, Velleja Research, 20125 Milano, Italy.
Alexander BertuccioliMicrobiota International Clinical Society, 10123 Torino, Italy.ORCID 0000-0002-3922-9115
Chiara Maria PalazziMicrobiota International Clinical Society, 10123 Torino, Italy.
Ilaria CavecchiaMicrobiota International Clinical Society, 10123 Torino, Italy.ORCID 0009-0007-2326-2328
Mariarosaria MateraMicrobiota International Clinical Society, 10123 Torino, Italy.ORCID 0009-0008-2115-1701
Edoardo LabriniAAT-Advanced Analytical Technologies, Fiorenzuola d'Arda, 29017 Piacenza, Italy.
Valeria SaghedduAAT-Advanced Analytical Technologies, Fiorenzuola d'Arda, 29017 Piacenza, Italy.
Sara SoldiAAT-Advanced Analytical Technologies, Fiorenzuola d'Arda, 29017 Piacenza, Italy.ORCID 0000-0001-5670-1306

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent investigations have highlighted, both experimentally and clinically, that probiotic strains equipped with arabinofuranosidase, in particular

Indexed as

abfAabfBarabinofuranosidegastrointestinal motility

Identifiers

PMID39203468
PMCPMC11356487

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.